CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer

dc.contributor.buuauthorTunca, Berrin
dc.contributor.buuauthorEgeli, Ünal
dc.contributor.buuauthorÇeçener, Gülşah
dc.contributor.buuauthorTezcan, Gülçin
dc.contributor.buuauthorGökgöz, Şehsuvar
dc.contributor.buuauthorTaşdelen, İsmet
dc.contributor.buuauthorBayram, Nuran
dc.contributor.buuauthorTolunay, Şahsine
dc.contributor.buuauthorUmut, Görkem
dc.contributor.buuauthorDemirdöğen, Elif
dc.contributor.buuauthorErtürk, Elif
dc.contributor.buuauthorAk, Seçil
dc.contributor.buuauthorÇetintaş, Sibel
dc.contributor.buuauthorEvrensel, Türkkan
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Biyoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Genel Cerrahi Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/İktisadi ve İdari Bilimler Fakültesi/Ekonometri Bölümü.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Patoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Radyasyon Onkolojisi Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Tıbbi Onkoloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0001-5492-184Xtr_TR
dc.contributor.orcid0000-0002-9732-5340tr_TR
dc.contributor.orcid0000-0002-3820-424Xtr_TR
dc.contributor.orcid0000-0001-7904-883Xtr_TR
dc.contributor.orcid0000-0002-1619-6680tr_TR
dc.contributor.orcid0000-0002-5956-8755tr_TR
dc.contributor.orcid0000-0002-9038-0515tr_TR
dc.contributor.orcid0000-0002-4483-9284tr_TR
dc.contributor.researcheridAAG-9068-2021tr_TR
dc.contributor.researcheridAAA-7047-2020tr_TR
dc.contributor.researcheridAAH-3843-2020tr_TR
dc.contributor.researcheridAAJ-1027-2021tr_TR
dc.contributor.researcheridAAP-9988-2020tr_TR
dc.contributor.researcheridAAH-1420-2021tr_TR
dc.contributor.researcheridABI-6078-2020tr_TR
dc.contributor.researcheridAAI-1612-2021tr_TR
dc.contributor.researcheridF-8554-2017tr_TR
dc.contributor.scopusid6602965754tr_TR
dc.contributor.scopusid55665145000tr_TR
dc.contributor.scopusid6508156530tr_TR
dc.contributor.scopusid25650627600tr_TR
dc.contributor.scopusid6603238737tr_TR
dc.contributor.scopusid9637821500tr_TR
dc.contributor.scopusid13609585600tr_TR
dc.contributor.scopusid6602604390tr_TR
dc.contributor.scopusid37058220200tr_TR
dc.contributor.scopusid25644460900tr_TR
dc.contributor.scopusid50261655300tr_TR
dc.contributor.scopusid55253485700tr_TR
dc.contributor.scopusid6505881756tr_TR
dc.contributor.scopusid6603942124tr_TR
dc.date.accessioned2022-10-03T06:28:28Z
dc.date.available2022-10-03T06:28:28Z
dc.date.issued2012
dc.description.abstractAims and background. The major cause of death in breast cancer patients is metastasis. Various biomarkers have been used for the early detection of circulating tumor cells in the peripheral blood of breast cancer patients. The aims of the current study were to analyze circulating tumor cells in the blood of breast cancer patients by investigating EGFR, CK19, CK20 and HER2 expression profiles and to evaluate their prognostic importance. Methods. CK19, CK20 and EGFR gene expression profiles were evaluated in the blood samples of 84 female patients with primary invasive ductal breast cancer and 20 healthy female volunteers using SYBR green-based real-time qPCR assays. HER2 expression analyses were conducted in 46 patients who had an HER2-positive primary tumor and in 30 healthy women to determine the cutoff level of positivity. Results. The positive rates of CK20, EGFR, CK19 and HER2 mRNA expression in the peripheral blood were 28.57% (24/84), 20.23% (17/84), 5.95% (5/84) and 2.17% (1/46), respectively. The high positive ratio of CK20 mRNA expression in the peripheral blood of breast cancer was identified for the first time in the current study. Significant differences were identified in CK20 expression status and several clinical parameters related with aggressiveness of tumors using a binary logistic regression analysis. Higher CK20-positive levels were observed in patients who had lymph node metastasis and advanced-grade primary tumors, which were estrogen receptor-negative. We have demonstrated that CK20 may be a novel biomarker that is useful to identify circulating tumor cells and predict breast cancer progression. Conclusions. The results suggest that the investigation of CK20 mRNA with other biomarkers in the peripheral blood of breast cancer patients may be useful to monitor the presence of disseminated tumor cells in the blood circulation and to predict the prognosis of breast cancer.en_US
dc.identifier.citationTunca, B. vd. (2012). "CK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast cancer". Tumori Journal, 98(2), 243-251.en_US
dc.identifier.endpage251tr_TR
dc.identifier.issn0300-8916
dc.identifier.issn2038-2529
dc.identifier.issue2tr_TR
dc.identifier.pubmed22677992tr_TR
dc.identifier.scopus2-s2.0-84864881515tr_TR
dc.identifier.startpage243tr_TR
dc.identifier.urihttps://doi.org/10.1177/030089161209800211
dc.identifier.urihttps://journals.sagepub.com/doi/10.1177/030089161209800211
dc.identifier.urihttp://hdl.handle.net/11452/28913
dc.identifier.volume98tr_TR
dc.identifier.wos000305546600011tr_TR
dc.indexed.pubmedPubMeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherSage Publicationsen_US
dc.relation.journalTumori Journalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectOncologyen_US
dc.subjectBreast canceren_US
dc.subjectCirculating tumor cellsen_US
dc.subjectPrognosisen_US
dc.subjectRna-positive cellsen_US
dc.subjectPolymerase-chain-reactionen_US
dc.subjectMammaglobin messenger-rnaen_US
dc.subjectTranscription-pcr assayen_US
dc.subjectPeripheral-blooden_US
dc.subjectColorectal-canceren_US
dc.subjectMolecular-detectionen_US
dc.subjectPrognostic valueen_US
dc.subjectRt-pcren_US
dc.subjectAdjuvant chemotherapyen_US
dc.subject.emtreeCytokeratin 19en_US
dc.subject.emtreeCytokeratin 20en_US
dc.subject.emtreeEpidermal growth factor receptoren_US
dc.subject.emtreeEpidermal growth factor receptor 2en_US
dc.subject.emtreeMessenger rnaen_US
dc.subject.emtreeTumor markeren_US
dc.subject.emtreeERBB2 proteinen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAdvanced canceren_US
dc.subject.emtreeAgeden_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeBlood samplingen_US
dc.subject.emtreeBreast carcinomaen_US
dc.subject.emtreeCancer prognosisen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeCytokeratin 19 geneen_US
dc.subject.emtreeCytokeratin 20 geneen_US
dc.subject.emtreeEpidermal growth factor receptor geneen_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeGene expression profilingen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman cellen_US
dc.subject.emtreeLymph node metastasisen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeOncogeneen_US
dc.subject.emtreeOncogene neuen_US
dc.subject.emtreePrimary tumoren_US
dc.subject.emtreeProtein expressionen_US
dc.subject.emtreeReal time polymerase chain reactionen_US
dc.subject.emtreeTumor cellen_US
dc.subject.emtreeBlooden_US
dc.subject.emtreeBreast tumoren_US
dc.subject.emtreeCancer gradingen_US
dc.subject.emtreeCancer stagingen_US
dc.subject.emtreeChemistryen_US
dc.subject.emtreeDisease free survivalen_US
dc.subject.emtreeEarly diagnosisen_US
dc.subject.emtreeGene expression regulationen_US
dc.subject.emtreeGeneticsen_US
dc.subject.emtreeLymph node metastasisen_US
dc.subject.emtreeMiddle ageden_US
dc.subject.emtreePaget nipple diseaseen_US
dc.subject.emtreePathologyen_US
dc.subject.emtreePredictive valueen_US
dc.subject.emtreePrognosisen_US
dc.subject.emtreeReceiver operating characteristicen_US
dc.subject.emtreeRisken_US
dc.subject.emtreeSensitivity and specificityen_US
dc.subject.emtreeStatistical modelen_US
dc.subject.emtreeTumor embolismen_US
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshBreast neoplasmsen_US
dc.subject.meshCarcinoma, ductal, breasten_US
dc.subject.meshDisease-free survivalen_US
dc.subject.meshEarly detection of canceren_US
dc.subject.meshFemaleen_US
dc.subject.meshGene expression profilingen_US
dc.subject.meshGene expression regulation, neoplasticen_US
dc.subject.meshHumansen_US
dc.subject.meshKeratin-19en_US
dc.subject.meshKeratin-20en_US
dc.subject.meshLogistic modelsen_US
dc.subject.meshLymphatic metastasisen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshNeoplasm gradingen_US
dc.subject.meshNeoplasm stagingen_US
dc.subject.meshNeoplastic cells, circulatingen_US
dc.subject.meshOdds ratioen_US
dc.subject.meshPredictive value of testsen_US
dc.subject.meshPrognosisen_US
dc.subject.meshReal-time polymerase chain reactionen_US
dc.subject.meshReceptor, epidermal growth factoren_US
dc.subject.meshReceptor, erbB-2tr_TR
dc.subject.meshRna, messengertr_TR
dc.subject.meshRoc curveen_US
dc.subject.meshSensitivity and specificityen_US
dc.subject.meshTumor markers, biologicalen_US
dc.subject.scopusCirculating Neoplastic Cells; Liquid Biopsy; Circulating Tumor DNAen_US
dc.subject.wosOncologyen_US
dc.titleCK19, CK20, EGFR and HER2 status of circulating tumor cells in patients with breast canceren_US
dc.typeArticle

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: